12.Gjerstorff MF, Pohl M, Olsen KE, & Ditzel HJ (2013) Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer 13:466. 13.Hibi K, et al. (1999) PGP9.5 as a candidate tumor marker for non-small-cell lung ca...
31: A new NHS diagnostic service to detect EGFR ctDNA mutations in non-small cell lung cancer patients - ScienceDirectBackground/Aim: In advanced non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) mutations L858R and exon 19 deletion (del19) predict response to ...
van den Heuvel MM, Verheij M, Boshuizen R, et al. NHS⁃IL2 com⁃ bined with radiotherapy: Preclinical rationale and phase Ib trial re⁃ sults in metastatic non⁃small cell lung cancer following first⁃line chemotherapy[ J] . J Transl Med,2015,13:32....
osimertinib will now be an option forpatientswhose nonsmall cell lung cancer(NSCLC) has begun to spread to other parts of the body and who have not yet received treatment for their cancer. These cancer cells would also need to test positive for a faulty version...
Certain untreated lung cancer patients on England's NHS will have to make do with older drugs after NICE ruled in final guidance that AstraZeneca’s Tagrisso (osimertinib) is not cost-effective in this use.
The Scottish Medical Consortium (SMC) approved the use of two new treatment options—dacomitinib (Vizimpro) and pembrolizumab (Keytruda) – for some patients with nonsmall cell lung cancer. But a thirdlung cancerdrug, osimertinib, has been rejected by the SMC as it was deemed to not provide...
TheCE-IVD marked Aiforia® Clinical AI Model for Lung Cancer; PD-L1is intended for use by pathologists in supporting them with the detection and calculation of PD-L1 biomarker levels in non-small cell lung cancer cases. The clinical grade deep learning artificial intelligence model can automati...
202 Management of stage I and II non-small cell lung cancer at Plymouth Hospitals NHS Trust S Iyer,A Roy,A Marchbank - 《Lung Cancer》 被引量: 1发表: 2013年 Management of stage I and II non-small cell lung cancer at Plymouth Hospitals NHS Trust Iyer,S.,Roy,... - 《Lung Cancer ...
- 《Cancer Research》 被引量: 234发表: 2009年 A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic e... To assess the impact of fractionation upon tumor control and toxicity in medically inoperable...
Lung Cancer Drug Approval ALK-inhibitor brigatinib (Alunbrig, Takeda) was recommended by NICE for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib (Xalkori, Pfizer). An assessment of clinical evidence suggested...